Relationship between baseline D-dimer and prognosis in Japanese patients with venous thromboembolism: Insights from the J’xactly study
暂无分享,去创建一个
Y. Okumura | T. Yamazaki | N. Yamada | Mashio Nakamura | T. Yamashita | I. Fukuda | M. Takayama | T. Ikeda | A. Hirayama | Hideaki Maeda | M. Mo | Shohei Migita
[1] Y. Okumura,et al. A Multicenter Prospective Observational Cohort Study to Investigate the Effectiveness and Safety of Rivaroxaban in Japanese Venous Thromboembolism Patients (The J'xactly Study). , 2020, Circulation journal : official journal of the Japanese Circulation Society.
[2] M. Toyofuku,et al. D-dimer levels at diagnosis and long-term clinical outcomes in venous thromboembolism: from the COMMAND VTE Registry , 2019, Journal of Thrombosis and Thrombolysis.
[3] B. Sobkowicz,et al. Atrial Fibrillation in Patients with Acute Pulmonary Embolism: Clinical Significance and Impact on Prognosis , 2019, BioMed research international.
[4] Pengfei Guo,et al. A meta-analysis of randomized controlled trials , 2019, Medicine.
[5] A. Singer,et al. D‐dimer levels in VTE patients with distal and proximal clots☆ , 2019, The American journal of emergency medicine.
[6] Y. Okumura,et al. Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J’xactly) study , 2018, BMJ Open.
[7] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[8] Ming Zhang,et al. Update on the Management of Patent Foramen Ovale in 2017: Indication for Closure and Literature Review , 2017 .
[9] Y. Smulders,et al. Never ignore extremely elevated D-dimer levels: they are specific for serious illness. , 2016, The Netherlands journal of medicine.
[10] Jose Luis Zamorano,et al. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS) , 2014 .
[11] G. Raskob,et al. Thrombosis: A major contributor to global disease burden , 2014, Thrombosis and Haemostasis.
[12] G. Raskob,et al. Thrombosis: a major contributor to the global disease burden , 2014, Journal of thrombosis and haemostasis : JTH.
[13] G. Raskob,et al. Thrombosis: A Major Contributor to Global Disease Burden , 2014, Seminars in Thrombosis & Hemostasis.
[14] G. Lippi,et al. Aging Hemostasis: Changes to Laboratory Markers of Hemostasis As We Age—A Narrative Review , 2014, Seminars in Thrombosis & Hemostasis.
[15] E. Akl,et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[16] Jeroen J. Bax,et al. ESC Guidelines on the diagnosis and management of acute pulmonary embolism , 2014 .
[17] T. Ohmori,et al. Distinct reactivity of the commercially available monoclonal antibodies of D-dimer and plasma FDP testing to the molecular variants of fibrin degradation products. , 2013, Thrombosis research.
[18] Adrian V. Hernández,et al. Timing of recurrent venous thromboembolism early after the index event: a meta-analysis of randomized controlled trials. , 2013, Thrombosis research.
[19] J. Reitsma,et al. Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: systematic review and meta-analysis , 2013, BMJ.
[20] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[21] Paolo Prandoni,et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[22] Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). , 2011, Circulation journal : official journal of the Japanese Circulation Society.
[23] S. Ogawa,et al. D-Dimer Levels in Combination with Clinical Risk Factors Can Effectively Predict Subsequent Thromboembolic Events in Patients with Atrial Fibrillation during Oral Anticoagulant Therapy , 2010, Cardiology.
[24] Samuel Z Goldhaber,et al. Venous thromboembolism and atherothrombosis: an integrated approach. , 2010, Circulation.
[25] D. Jiménez,et al. D‐dimer levels and 15‐day outcome in acute pulmonary embolism. Findings from the RIETE Registry , 2009, Journal of thrombosis and haemostasis : JTH.
[26] Joe McCarthy,et al. An integrated approach , 2001 .
[27] G. Raskob,et al. Idraparinux versus standard therapy for venous thromboembolic disease. , 2007, The New England journal of medicine.
[28] R. Lecumberri,et al. D-dimer levels correlate with mortality in patients with acute pulmonary embolism: Findings from the RIETE registry , 2007, Critical care medicine.
[29] J. Cornuz,et al. Prognostic value of D-dimer in patients with pulmonary embolism , 2006, Thrombosis and Haemostasis.
[30] S. Doucette,et al. Does this patient have deep vein thrombosis? , 1998, JAMA.
[31] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.
[32] William A Ghali,et al. d-Dimer for the Exclusion of Acute Venous Thrombosis and Pulmonary Embolism , 2004, Annals of Internal Medicine.
[33] M Gent,et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. , 2003, The New England journal of medicine.
[34] D. Slosman,et al. Prediction of Pulmonary Embolism Extent by Clinical Findings, D-dimer Level and Deep Vein Thrombosis Shown by Ultrasound , 2001, Thrombosis and Haemostasis.
[35] G. Kovacs,et al. Excluding Pulmonary Embolism at the Bedside without Diagnostic Imaging: Management of Patients with Suspected Pulmonary Embolism Presenting to the Emergency Department by Using a Simple Clinical Model and d-dimer , 2001, Annals of Internal Medicine.
[36] S. Amitani,et al. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. , 1997, Journal of the American College of Cardiology.
[37] G. Lip,et al. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. , 1996, Circulation.
[38] T. Kamada,et al. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. , 1990, Journal of the American College of Cardiology.
[39] A A Connolly,et al. Deep vein thrombosis. , 1988, BMJ.